Synthesis of ribozyme against vascular endothelial growth factor165 and its biological activity in vitro

World Journal of Gastroenterology

Volumn 10, Issue 10, 2004, Pages 1495-1498

  Gu, Zhong Ping ^a   Wang, Yun Jie ^a   Wu, Yu ^a   Li, Jin Ge ^a   Chen, Nong An ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; RIBOZYME; VASCULOTROPIN;

ARTICLE; CELL FREE SYSTEM; COMPUTER SYSTEM; EXPRESSION VECTOR; GENE ACTIVITY; GENETIC TRANSCRIPTION; IN VITRO STUDY; RNA CLEAVAGE; RNA SYNTHESIS;

EID: 4444252007     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v10.i10.1495     Document Type: Article

References (42)

1. Doherty EA, Doudna JA. Ribozyme structures and mechanisms. Annu Rev Biophys Biomol Struct 2001; 30: 457-475
2. Takagi Y, Warashina M, Stec WJ, Yoshinari K, Taira K. Recent advances in the elucidation of the mechanisms of action of ribozymes. Nucleic Acids Res 2001; 29: 1815-1834
3. Aigner A, Renneberg H, Bojunga J, Apel J, Nelson PS, Czubayko F. Ribozyme-targeting of a secreted FGF-binding protein (FGF-BP) inhibits proliferation of prostate cancer cells in vitro and in vivo. Oncogene 2002; 21: 5733-5742
4. Li JG, Lian JQ, Jia ZS, Feng ZH, Nie QH, Wang JP, Huang CX, Bai XF. Effect of ribozymes on inhibiting expression of HBV mRNA in HepG2 cells. Shijie Huaren Xiaohua Zazhi 2003; 11: 161-164
5. Tekur S, Ho SM. Ribozyme-mediated downregulation of human metallothionein II(a) induces apoptosis in human prostate and ovarian cancer cell lines. Mol Carcinog 2002; 33: 44-55
6. Lin JS, Song YH, Kong XJ, Li B, Liu NZ, Wu XL, Jin YX. Preparation and identification of anti-transforming growth factor beta1 U1 small nuclear RNA chimeric ribozyme in vitro. World J Gastroenterol 2003; 9: 572-577
7. Zheng Y, Zhang J, Qu L. Effects of anti-HPV16E6-ribozyme on phenotype and gene expression of a cervical cancer cell line. Chin Med J 2002; 115: 1501-1506
8. Jia ZS, Chen L, Hao CQ, Feng ZH, Li JG, Wang JP, Cao YZ, Zhou YX. Intracellular immunization by hammerhead ribozyme against HCV. Shijie Huaren Xiaohua Zazhi 2003; 11: 148-150
9. Castanotto D, Li JR, Michienzi A, Langlois MA, Lee NS, Puymirat J, Rossi JJ. Intracellular ribozyme applications. Biochem Soc Trans 2002; 30(Pt 6): 1140-1145
10. Liu XJ, Wu QM, Liu CZ, Yu JP, Wang Q. Construction and assessment of eukaryotic expression plasmid pBBS212Rz containing ribozyme gene against hTR. Shijie Huaren Xiaohua Zazhi 2002; 10: 1261-1263
11. Tong Q, Zhao J, Chen Z, Zeng F, Lu G. Effects of blocking androgen receptor expression with specific hammerhead ribozyme on in vitro growth of prostate cancer cell line. Chin Med J 2003; 116: 1515-1518
12. Goodchild J. Hammerhead ribozymes for target validation. Expert Opin Ther Targets 2002; 6: 235-247
13. Goodchild J. Hammerhead ribozymes: biochemical and chemical considerations. Curr Opin Mol Ther 2000; 2: 272-281
14. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9: 653-660
15. Gu ZP, Wang YJ, Li JG, Zhou YA. VEGF165 antisense RNA suppresses oncogenic properties of human esophageal squamous cell carcinoma. World J Gastroenterol 2002; 8: 44-48
16. Hughes GC, Biswas SS, Yin B, Coleman RE, DeGrado TR, Landolfo CK, Lowe JE, Annex BH, Landolfo KP. Therapeutic angiogenesis in chronically ischemic porcine myocardium: comparative effects of bFGF and VEGF. Ann Thorac Surg 2004; 77: 812-818
17. Fernandez M, Vizzutti F, Garcia-Pagan JC, Rodes J, Bosch J. Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. Gastroenterology 2004; 126: 886-894
18. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 145-147
19. Fondevila C, Metges JP, Fuster J, Grau JJ, Palacin A, Castells A, Volant A, Pera M. p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br J Cancer 2004; 90: 206-215
20. Van Trappen PO, Steele D, Lowe DG, Baithun S, Beasley N, Thiele W, Weich H, Krishnan J, Shepherd JH, Pepper MS, Jackson DG, Sleeman JP, Jacobs IJ. Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis. J Pathol 2003; 201: 544-554
21. Buchler P, Reber HA, Ullrich A, Shiroiki M, Roth M, Buchler MW, Lavey RS, Friess H, Hines OJ. Pancreatic cancer growth is inhibited by blockade of VEGF-RII. Surgery 2003; 134: 772-782
22. Belotti D, Paganoni P, Manenti L, Garofalo A, Marchini S, Taraboletti G, Giavazzi R. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res 2003; 63: 5224-5229
23. Li Q, Dong X, Gu W, Qiu X, Wang E. Clinical significance of coexpression of VEGF-C and VEGFR-3 in non-small cell lung cancer. Chin Med J 2003; 116: 727-730
24. Qi JH, Ebrahem Q, Moore N, Murphy G, Claesson-Welsh L, Bond M, Baker A, Anand-Apte B. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 2003; 9: 407-415
25. LeCouter J, Lin R, Ferrara N. Endocrine gland-derived VEGF and the emerging hypothesis of organ-specific regulation of angiogenesis. Nat Med 2002; 8: 913-917
26. Riedel F, Gotte K, Li M, Hormarm K, Grandis JR. Abrogation of VEGF expression in human head and neck squamous cell carcinoma decreases angiogenic activity in vitro and in vivo. Int J Oncol 2003; 23: 577-583
27. Ferrara N. Role of vascular endothelial growth factor in physiologic and patholopic angiogenesis: therapeutic implications. Semin Oncol 2002; 29(6 Suppl 16): 10-14
28. Bikfalvi A, Bicknell R. Recent advances in angiogenesis, anti-angiogenesis and vascular targeting. Trends Pharmacol Sci 2002; 23: 576-582
29. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20: 4368-4380
30. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002; 2: 795-803
31. Hasan J, Byers R, Jayson GC. Intra-tumoural microvessel density in human solid tumours. Br J Cancer 2002; 86: 1566-1577
32. Chiarug V, Ruggiero M, Magnelli L. Angiogenesis and the unique nature of tumor matrix. Mol Biotechnol 2002; 21: 85-90
33. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-257
34. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242-248
35. Sun LQ, Cairns MJ, Saravolac EG, Baker A, Gerlach WL. Catalytic nucleic acids: from lab to applications. Pharmacol Rev 2000; 52: 325-347
36. Takagi Y, Suyama E, Kawasaki H, Miyagishi M, Taira K. Mechanism of action of hammerhead ribozymes and their applications in vivo: rapid identification of functional genes in the post-genome era by novel hybrid ribozyme libraries. Biochem Soc Trans 2002; 30(Pt 6): 1145-1149
37. Blount KF, Uhlenbeck OC. The hammerhead ribozyme. Biochem Soc Trans 2002; 30(Pt 6): 1119-1122
38. Amarzguioui M, Prydz H. Hammerhead ribozyme design and application. Cell Mol Life Sci 1998; 54: 1175-1202
39. Pennati M, Binda M, Colella G, Zoppe' M, Folini M, Vignati S, Valentini A, Citti L, De Cesare M, Pratesi G, Giacca M, Daidone MG, Zaffaroni N. Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells. Oncogene 2004; 23: 386-394
40. Weng DE, Usman N. Angiozyme: a novel angiogenesis inhibitor. Curr Oncol Rep 2001; 3: 141-146
41. Brattstrom D, Bergqvist M, Hesselius P, Larsson A, Wagenius G, Brodin O. Serum VEGF and bFGF adds prognostic information in patients with normal platelet counts when sampled before, during and after treatment for locally advanced non-small cell lung cancer. Lung Cancer 2004; 43: 55-62
42. Im SA, Kim JS, Gomez-Manzano C, Fueyo J, Liu TJ, Cho MS, Seong CM, Lee SN, Hong YK, Yung WK. Inhibition of breast cancer growth in vivo by antiangiogenesis gene therapy with adenovirus-mediated antisense-VEGF. Br J Cancer 2001; 84: 1252-1257